

INJECTABLE FORMULATIONS CONTAINING SUCCINATE

ABSTRACT OF THE DISCLOSURE

- 5           The invention is directed to formulations of a pharmaceutically active agent  
for *in vivo* use. The formulations to which the invention is directed are designed to  
minimize the pain associated with components in injectable formulations, other than  
the pharmaceutically active agent. The invention is particularly directed to buffers  
that provide for minimum pain upon injection. Insulin-like growth factor I (IGF-I) is  
10 a preferred pharmaceutically active agent.

09285429 "040209  
662040" 62458250